222 related articles for article (PubMed ID: 16488321)
21. Treatment of erythrodermic psoriasis with etanercept.
Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
[TBL] [Abstract][Full Text] [Related]
22. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
23. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.
Campione E; Mazzotta A; Paternò EJ; Diluvio L; Prinz JC; Chimenti S
Acta Derm Venereol; 2009; 89(3):288-91. PubMed ID: 19479128
[TBL] [Abstract][Full Text] [Related]
24. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
25. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
Bagel J; Lynde C; Tyring S; Kricorian G; Shi Y; Klekotka P
J Am Acad Dermatol; 2012 Jul; 67(1):86-92. PubMed ID: 22014541
[TBL] [Abstract][Full Text] [Related]
26. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
Leonardi C; Strober B; Gottlieb AB; Elewski BE; Ortonne JP; van de Kerkhof P; Chiou CF; Dunn M; Jahreis A
J Drugs Dermatol; 2010 Aug; 9(8):928-37. PubMed ID: 20684143
[TBL] [Abstract][Full Text] [Related]
28. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.
De Felice C; Mazzotta A; Esposito M; Bianchi L; Chimenti S
J Dermatolog Treat; 2006; 17(6):355-8. PubMed ID: 17853309
[TBL] [Abstract][Full Text] [Related]
29. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study.
Mazzotta A; Esposito M; Schipani C; Chimenti S
J Dermatolog Treat; 2009; 20(6):354-8. PubMed ID: 19954392
[TBL] [Abstract][Full Text] [Related]
30. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
[TBL] [Abstract][Full Text] [Related]
31. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
32. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
Cassano N; Loconsole F; Galluccio A; Miracapillo A; Pezza M; Vena GA
Int J Immunopathol Pharmacol; 2006; 19(1):225-9. PubMed ID: 16569361
[TBL] [Abstract][Full Text] [Related]
33. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
[TBL] [Abstract][Full Text] [Related]
34. Our experience with etanercept in the treatment of psoriasis.
Kokelj F; Miertusova Tothova S; Patamia M; Trevisan G
Acta Dermatovenerol Croat; 2006; 14(4):241-5. PubMed ID: 17311738
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
[TBL] [Abstract][Full Text] [Related]
36. Puerto Rico psoriasis study group: efficacy and safety of etanercept.
González-Chavez JR; Berlingeri-Ramos AC; Sánchez Casiano MA
J Drugs Dermatol; 2005; 4(6):735-9. PubMed ID: 16302559
[TBL] [Abstract][Full Text] [Related]
37. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
[TBL] [Abstract][Full Text] [Related]
38. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.
Gottlieb AB; Leonardi CL; Goffe BS; Ortonne JP; van der Kerkhof PC; Zitnik R; Nakanishi A; Jahreis A
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S92-100. PubMed ID: 16488335
[TBL] [Abstract][Full Text] [Related]
39. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept.
Wolf P; Hofer A; Legat FJ; Bretterklieber A; Weger W; Salmhofer W; Kerl H
Br J Dermatol; 2009 Jan; 160(1):186-9. PubMed ID: 19067710
[TBL] [Abstract][Full Text] [Related]
40. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
